2025-04-02 - Analysis Report
## Teva Pharmaceutical Industries Ltd ADR (TEVA) Stock Report

**0) Overview:**

Teva Pharmaceutical Industries Ltd ADR (TEVA) is a global pharmaceutical company.

**1) Performance Comparison and Alpha/Beta Analysis:**

TEVA's cumulative return (22.96%) significantly underperformed the S&P 500 (VOO) with a cumulative return of 89.83%. The difference is -66.9%, placing it at the 46.1st percentile of its historical range of underperformance (-137.9% to 16%).

The provided Alpha/Beta analysis reveals consistently negative alpha values across all periods, indicating underperformance relative to the market benchmark.  The beta values fluctuate, suggesting varying levels of market sensitivity.  The high beta in 2022-2024 (25.1) indicates significant market sensitivity during that period.  Note that negative alpha consistently demonstrates underperformance compared to the market.

| Year       | CAGR    | MDD     | Alpha   | Beta    | Cap(B) |
|------------|---------|---------|---------|---------|--------|
| 2015-2017  | -42.0%  | 50.4%   | -59.0%  | -0.1    | 21.6   |
| 2016-2018  | -47.0%  | 50.4%   | -53.0%  | -0.1    | 17.5   |
| 2017-2019  | -19.0%  | 50.4%   | -39.0%  | -0.1    | 11.2   |
| 2018-2020  | -5.0%   | 48.3%   | -39.0%  | -0.1    | 11.0   |
| 2019-2021  | -19.0%  | 41.2%   | -92.0%  | -0.1    | 9.1    |
| 2020-2022  | 9.0%    | 57.9%   | -2.0%   | -0.1    | 10.4   |
| 2021-2023  | 11.0%   | 57.9%   | -7.0%   | -0.4    | 11.9   |
| 2022-2024  | 96.0%   | 57.9%   | 74.0%   | -0.3    | 25.1   |
| 2023-2025  | 56.0%   | 75.6%   | 15.0%   | -0.1    | 17.5   |


**2) Recent Price Movements:**

* **Closing Price:** $15.37
* **Last Market Price:** $15.265 (a decrease of $0.68)
* **5-day Moving Average:** $15.466
* **20-day Moving Average:** $15.8835
* **60-day Moving Average:** $17.8628

The price is below all three moving averages, suggesting a downtrend.  The recent price drop (-0.68) is notable.

**3) Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4403 (Medium Risk)
* **RSI:** 37.79 (below 40, suggesting oversold conditions)
* **PPO:** -0.1086 (negative, indicating bearish momentum)
* **Recent Relative Divergence Change (20-day):** -2.6 (short-term downtrend)
* **Expected Return:** -100.3%  This extremely negative expected return needs further clarification.  It's likely referencing a significant underperformance compared to the S&P 500 over a long-term horizon (2+ years), not a loss of 100.3% of the initial investment.  The provided data doesn't justify such a dramatic figure.  Additional context is required.


**4) Recent Earnings Analysis:**

| Date       | EPS      | Revenue     |
|------------|----------|-------------|
| 2024-11-06 | -$0.39   | $4.33B      |
| 2024-07-31 | -$0.75   | $4.16B      |
| 2024-05-08 | -$0.12   | $3.82B      |
| 2023-11-09 | $0.07    | $3.85B      |
| 2024-02-12 | $0.06    | $3.85B      |

Recent earnings show fluctuating results, with both profits and losses. The most recent quarter shows negative EPS. Revenue remains relatively stable, but the trend is not definitively positive or negative.

**5) Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue     | Profit Margin |
|-------------|-------------|---------------|
| 2024-12-31  | $4.23B      | 50.15%        |
| 2024-09-30  | $4.33B      | 49.60%        |
| 2024-06-30  | $4.16B      | 48.61%        |
| 2024-03-31  | $3.82B      | 46.37%        |
| 2023-12-31  | $4.46B      | 54.18%        |

Revenue shows some fluctuation, but generally remains in the $4B range. Profit margins have decreased from Q4 2023, raising concerns about profitability.

**Capital and Profitability:**

| Quarter     | Equity (B) | ROE (%)      |
|-------------|------------|--------------|
| 2024-12-31  | $5.37      | -4.04%       |
| 2024-09-30  | $6.07      | -7.21%       |
| 2024-06-30  | $6.36      | -13.30%      |
| 2024-03-31  | $7.28      | -1.91%       |
| 2023-12-31  | $7.51      | 5.72%        |

Equity has decreased significantly since the end of 2023, and ROE is consistently negative, suggesting concerns about the company's profitability and return on investment.

**6) Overall Analysis:**

TEVA is currently underperforming the market significantly, as evidenced by its negative alpha and substantial lag behind the S&P 500. Technical indicators suggest oversold conditions, but negative PPO and downward price trends indicate continued bearish pressure. Recent earnings show mixed results, and the declining profit margins and negative ROE raise significant financial concerns.  The drastically negative expected return needs clarification, as the provided data does not support such a claim.  Before considering any investment, a deeper dive into the company's specific challenges and future outlook is crucial.  The negative trend is concerning, and further research is necessary to assess the long-term viability of TEVA.
